FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used to obtain a composition for the treatment of diseases associated with the overexpression of interleukin-15 (IL-15). The vaccine composition comprises a mutant human interleukin-15 (IL-15) polypeptide consisting of SEQ ID No. 1, at a concentration of 200-500 μg, at least one vaccine adjuvant selected from aluminum salts or water-in-oil emulsions, and pharmaceutically acceptable excipients or carriers, the concentration being 1.8 mg / ml, and the concentration of water emulsions in oil is 50:50 (v / v). The group of inventions also relates to the use of mutant human IL-15, defined as SEQ ID No. 1 to obtain a medicinal product.
EFFECT: use of this group of inventions makes it possible to induce a neutralizing antibody response against native human IL-15 by reducing the proliferation of CTLL-2 cells induced by this cytokine.
8 cl, 6 ex, 2 tbl, 5 dwg
| Title |
Year |
Author |
Number |
| IMMUNOGENIC PRODUCT CONTAINING IL-4 AND/OR IL-13 FOR TREATMENT OF DISORDERS ASSOCIATED WITH ABERRANT EXPRESSION OR ACTIVITY OF IL-4 AND/OR IL-13 |
2019 |
- Gruar-Vozhel, Zheraldin
- Konde Garsiya, Eva
- Bertran, Romejn
- Kajo, Noemi
- Reber, Loran
- Bruns, Per
- Serra, Vinsent
|
RU2809548C2 |
| RECOMBINANT PROTEINS AND THEIR APPLICATIONS IN THERAPEUTIC PURPOSES |
2018 |
- Charlton, Kit, Alan
- D'Ondt, Erik
|
RU2766595C2 |
| RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES |
2012 |
- Charlton Kit Alan
- D'Ondt Erik
|
RU2650574C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION |
2004 |
- Kollinz Mehri
- Shevach Ehtan Menakhem
- Makkh'Ju Rebekka S'Juzn
- Uitters Mehtt'Ju Dzhejms
- Jang Debora Ehnn
- Birn Majkl Chehpmen
- Reddi Padmalata F.
- Stefenz Dzhoffri Lorens
- Karreno Beatriz M.
|
RU2369636C2 |
| MUTANT ANTIGENS GAS57 AND GAS57 ANTIBODIES |
2008 |
- Margarit I Ros Immakulada
- Grandi Gvido
- Tsingaretti Chiara
|
RU2471497C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING |
2008 |
- Dzhaspers Stefehn R.
- Rikson Mark U.
- Dillon Stejsi R.
- Ramsdehll Frederik Dzh.
- Krejsa Sesil M.
- I Judzhin S.
|
RU2504552C2 |
| COMPOSITION FOR IMMUNIZATION (VARIANTS), METHOD FOR ITS PREPARING AND USING FOR TREATMENT OF ALLERGIC EOSINOPHILIC DISEASES |
2002 |
- Bakhmann Martin
- Dzhennings Gehri
- Zonderegger Ivo
|
RU2319503C2 |
| IMMUNOPROPHYLACTIC CANCER VACCINE |
2004 |
- Agadzhanjan, Majkl, G.
- Gochikjan, Anait
|
RU2556128C2 |
| HUMAN MODIFIED TNFα MOLECULE ABLE TO INDUCE FORMATION OF NEUTRALIZING ANTIBODY RAISED TO HUMAN TNFα, DNA ENCODING THEREOF, VECTOR (VARIANTS), METHOD FOR PREPARING, VACCINE AGAINST TNFα (VARIANTS), METHOD FOR TESTING FOR PRESENCE OF TNFα, METHOD FOR TESTING HUMAN BODY FLUID FOR PRESENCE OF TNFα, METHOD FOR DIAGNOSIS, METHOD FOR TREATMENT AND PROPHYLAXIS, MEDICINE FOR TREATMENT |
1998 |
- Jensen Martin Roland
- Mouritsen Seren
- Ehlsner Khenrik
- Dalum Iben
|
RU2241715C2 |
| PREVENTIVE CANCER VACCINE |
2004 |
- Agadzhanjan Majkl G.
- Gochikjan Anait
|
RU2385163C2 |
